Searching for rational anti-N-methyl-D-aspartate treatment for depression [5]

Archives of General Psychiatry

Volumn 64, Issue 9, 2007, Pages 1099-1100

  Tsai, Guochuan E ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

BINDING AFFINITY; COGNITIVE DEFECT; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HUMAN; LEARNING; LETTER; MEMORY; MEMORY DISORDER; NEUROPROTECTION; NEUROTOXICITY; PSYCHOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

COGNITION DISORDERS; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; N-METHYLASPARTATE; NEURODEGENERATIVE DISEASES; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 34548424490     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.64.9.1099     Document Type: Letter

References (10)

1. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.
2. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-155.
3. Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M, Kremer I. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93(1-3):239-243.
4. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006;97(6):1611-1626.
5. Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry. 2003;182:214-220.
6. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214.
7. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review [published online ahead of print September 28, 2006]. Psychopharmacology (Berl). 2006;188(4):408-424.
8. Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther. 1999;289(2):1060-1066.
9. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283(5398):70-74.
10. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7(1):32-43.